Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cucuribitane tetracyclic triterpenoids in resisting pulmonary fibrosis

一种四环三萜、葫芦烷型的技术，应用在肺纤维化的防治领域，能够解决尚无葫芦烷型四环三萜类化合物应用报道等问题，达到提取物活性明确、改善肺纤维化、广泛实用价值的效果

Active Publication Date: 2017-07-07
CHENGDU BIOPURIFY LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] So far, there is no report on the application of cucurbitane-type tetracyclic triterpenoids in anti-pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cucuribitane tetracyclic triterpenoids in resisting pulmonary fibrosis
  • Application of cucuribitane tetracyclic triterpenoids in resisting pulmonary fibrosis
  • Application of cucuribitane tetracyclic triterpenoids in resisting pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Mogroside IIIe improves bleomycin-induced mouse lung fibrosis

[0068] The above-mentioned mogroside IIIe was selected for the following in vivo pharmacodynamic studies. Intratracheal injection of bleomycin to induce pulmonary fibrosis in mice is a method commonly used in the world, and it is similar to human pulmonary interstitial fibrosis.

[0069] 1.1 Experimental method

[0070] ICR mice, male, weighing 25-30g, 100, provided by Yangzhou Comparative Medicine Center.

[0071] 20 mice were used as blank control group ( figure 1 The control group in), the other 80 are used for making models, all the above-mentioned mice are anesthetized by intraperitoneal injection of 4% chloral hydrate, the injection volume is 10ml / kg, after the mice are anesthetized, the mice are fixed and the necks of the mice are disinfected Cut the mouse neck skin longitudinally with scissors to expose the trachea; inject a syringe into the trachea, inject normal saline into the mice i...

Embodiment 2

[0094] Example 2 Mogroside IVe improves mouse lung fibrosis induced by bleomycin

[0095] The above-mentioned mogroside IVe (formula IV) was selected for the following in vivo pharmacodynamic studies.

[0096] 2.1 Experimental method

[0097] ICR mice, male, weighing 25-30g, 100, provided by Yangzhou Comparative Medicine Center.

[0098] 20 mice were used as the blank control group, and the other 80 were used for modeling. All the above-mentioned mice were anesthetized by intraperitoneal injection of 4% chloral hydrate, and the injection volume was 10ml / kg. After the mice were anesthetized, the mice were fixed and sterilized Neck of the mouse: cut the skin of the neck of the mouse longitudinally with scissors, and bluntly tear the fascia and muscles longitudinally with tweezers to expose the trachea; inject a syringe into the trachea, inject normal saline into the mice in the blank control group, and inject normal saline into the other mice Bleomycin (5mg / kg); then the mouse...

Embodiment 3

[0115] Example 3 Mogrosanol improves bleomycin-induced mouse lung fibrosis

[0116] The above-mentioned mogrosvenol (formula IX) was selected for the following in vivo pharmacodynamic studies.

[0117] 3.1 Experimental method

[0118] ICR mice, male, weighing 25-30g, 100, provided by Yangzhou Comparative Medicine Center.

[0119] 20 mice were used as the blank control group, and the other 80 were used for modeling. All the above-mentioned mice were anesthetized by intraperitoneal injection of 4% chloral hydrate, and the injection volume was 10ml / kg. After the mice were anesthetized, the mice were fixed and sterilized Neck of the mouse: cut the skin of the neck of the mouse longitudinally with scissors, and bluntly tear the fascia and muscles longitudinally with tweezers to expose the trachea; inject a syringe into the trachea, inject normal saline into the mice in the blank control group, and inject normal saline into the other mice Bleomycin (5mg / kg); then the mouse board w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of prevention and treatment of pulmonary fibrosis, and relates to an application of cucuribitane tetracyclic triterpenoids in resisting the pulmonary fibrosis. The invention provides the application of the cucuribitane tetracyclic triterpenoids in preparing medicines and / or health-care products for preventing and / or treating pulmonary fibrosis diseases. According to the invention, the novel pharmaceutical application of the cucuribitane tetracyclic triterpenoids, namely the application of the cucuribitane tetracyclic triterpenoids in preparing the medicines and / or health-care products for preventing and / or treating the pulmonary fibrosis diseases, is provided.

Description

technical field [0001] The invention belongs to the technical field of prevention and treatment of pulmonary fibrosis, and relates to the application of a cucurbitane-type tetracyclic triterpenoid compound in the preparation of medicines and / or health care products for preventing and / or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is a chronic interstitial lung disease characterized by the infiltration of inflammatory cells such as lymphocytes and macrophages in the pulmonary interstitium, the proliferation of fibroblasts, and the deposition of fibrous connective tissue in the pulmonary interstitium. . Pulmonary fibrosis is caused by various pathogenic factors inside and outside the lung, and is the result of a series of chronic lung injuries or the development of advanced diseases, which seriously endangers human health. The etiology of pulmonary fibrosis includes hereditary immune dysfunction, viral infection, drugs and chemicals, rad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/575A61P11/00A61P29/00
CPCA61K31/575A61K31/704A61P11/00
Inventor 谢海峰张朝凤谢期林胡云岭
Owner CHENGDU BIOPURIFY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com